Li Xuesen, Li Na, Niu Qinghui, Zhu Haibin, Wang Zhijie, Hou Qingxian
Department of Spine Surgery, The Affiliated Hospital of Qingdao University, Qingdao, Shandong 266555, People's Republic of China.
Department of Ophthalmology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong 266555, People's Republic of China.
Onco Targets Ther. 2020 Mar 2;13:1851-1857. doi: 10.2147/OTT.S232479. eCollection 2020.
Osteosarcoma (OS) is an invasive bone tumor that primarily affects children and adolescents. MicroRNA-629 (miR-629) acts as an oncogene involved in the development of various cancers. This study aims to reveal the clinical significance and biological function of miR-629 in OS.
The levels of miR-629 expression in tissues and cells were detected through quantitative real-time polymerase chain reaction (qRT-PCR). Chi-square test was used to evaluate the relationship between miR-621 expression and clinical parameters in patients with OS. Survival analysis was performed by the Kaplan-Meier method. Cox regression analysis of the effect of miR-629 expression on the prognosis of OS patients. CCK-8 and Transwell experiments were used to demonstrate the effect of miR-629 on OS cell function.
Compared with the controls, miR-629 levels were significantly elevated in patients with OS ( < 0.001), Furthermore, miR-629 upregulation showed significantly associated with clinical stage ( = 0.011), distant metastasis ( = 0.003) and poor survival (log rank test, = 0.013) in OS patients. miR-629 might be a potential prognostic biomarker for OS (HR = 2.890, 95% CI = 1.126-7.416, = 0.027). Cell function experiments proved that the high expression of miR-629 promoted cell proliferation, migration, and invasion of OS.
All experimental results demonstrated that miR-629 as an oncogene promotes the tumor cell growth, migration and invasion of OS, and miR-629 may act as a novel prognostic biomarker and therapeutic target for patients with this malignant tumor.
骨肉瘤（OS）是一种主要影响儿童和青少年的侵袭性骨肿瘤。微小RNA-629（miR-629）作为一种癌基因参与多种癌症的发生发展。本研究旨在揭示miR-629在骨肉瘤中的临床意义和生物学功能。
通过定量实时聚合酶链反应（qRT-PCR）检测组织和细胞中miR-629的表达水平。采用卡方检验评估骨肉瘤患者中miR-621表达与临床参数之间的关系。采用Kaplan-Meier法进行生存分析。对miR-629表达对骨肉瘤患者预后的影响进行Cox回归分析。采用CCK-8和Transwell实验证明miR-629对骨肉瘤细胞功能的影响。
与对照组相比，骨肉瘤患者中miR-629水平显著升高（<0.001）。此外，miR-6上调在骨肉瘤患者中与临床分期（=0.011）、远处转移（=0.003）及生存不良（log rank检验，=0.013）显著相关。miR-629可能是骨肉瘤的一个潜在预后生物标志物（HR=2.890，95%CI=1.126-7.416，=0.027）。细胞功能实验证明，miR-629的高表达促进了骨肉瘤细胞的增殖、迁移和侵袭。
所有实验结果表明，miR-629作为一种癌基因促进了骨肉瘤肿瘤细胞的生长、迁移和侵袭，miR-629可能作为这种恶性肿瘤患者的一种新型预后生物标志物和治疗靶点。
